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ABSTRACT
Laser interstitial thermal therapy (LITT) is an emerging
modality to treat benign and malignant brain lesions. LITT is
a minimally invasive method to ablate tissue using laser-
induced tissue heating and serves as both a diagnostic and
therapeutic modality for progressive brain lesions. We com-
pleted a single-center retrospective analysis of all patients
with progressive brain lesions treated with LITT since its
introduction at our center in August of 2015. Twelve
patients have been treated for a total of 13 procedures, of
which 10 patients had brain metastases and 2 patients had
primary malignant gliomas. Biopsies were obtained immedi-
ately prior to laser-induced tissue heating in 10 procedures
(76.9%), of which seven biopsies showed treatment-related
changes without viable tumor. After laser ablation, two of
three patients previously on steroids were successfully
weaned on first attempt. The results of this analysis indi-
cate that LITT is a well-tolerated procedure enabling some
patients to discontinue steroids that may be effective for
diagnosing and treating radiation necrosis and tumor pro-
gression. The Oncologist 2019;24:e1467–e1470
INTRODUCTION
Laser interstitial thermal therapy (LITT) is a minimally invasive
neurosurgical method to ablate tissue using laser-induced tis-
sue heating and is an emerging diagnostic and therapeutic
modality for progressive brain lesions. The risks of LITT include
neurologic deficits related to ablation of eloquent tissues,
treatment-related edema, intracranial hemorrhage, and wound
infection. Thin laser fiber probes allow for safe access to the
lesion in question, and biopsies can be obtained to help estab-
lish a diagnosis intraoperatively. Several barriers prevented its
use in the central nervous system (CNS), particularly the ability
to accurately and efficiently place laser fiber probes into the
brain to monitor rising tissue temperatures spatially. The devel-
opment of image-guidance platforms, including magnetic reso-
nance imaging (MRI) thermography, allowed accurate targeting
and monitoring of CNS lesions [1]. This thermography is crucial
to allow heating of target neoplastic tissues to threshold tem-
peratures for tissue death while limiting thermal injury to cru-
cial CNS structures. This combination of surgical stereotactic
laser fiber placement to thermally ablate tissues via LITT is a
U.S. Food and Drug Administration-approved minimally inva-
sive procedure. LITT was introduced as a diagnostic and thera-
peutic option at the University of Michigan in August of 2015.
Given the relative novelty of the procedure, there is a paucity
of data on the patient characteristics, clinical outcomes,
toxicities, and correlations between pathologic and radiologic
features in patients with cancer who have undergone LITT for
progressive brain lesions [2].
LITT provides a novel therapeutic opportunity for
addressing both radiation necrosis and local tumor progres-
sion. Following focal high-dose radiation, radiation-related
treatment effects or radiation necrosis may be observed, man-
ifesting as enlargement of the treated, contrast-enhancing
lesion on standard MRI [3]. Treatment effects are difficult to
distinguish from actual tumor progression, which has a similar
appearance. The gold standard to distinguish between these
two scenarios is biopsy; however, obtaining tissue previously
required invasive craniotomy, for which a minority of patients
are eligible. Therefore, there is a critically unmet need to iden-
tify noninvasive approaches for assessing patients with these
imaging findings after treatment to establish an accurate diag-
nosis and guide optimal management.
MATERIALS AND METHODS
We identified cancer patients who have undergone LITT
when clinically indicated for treatment of progressive contrast-
enhancing lesions at the University of Michigan Rogel Compre-
hensive Cancer Center since the procedure was introduced in
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August 2015. Institutional review board approval was obtained.
Demographic and clinical features were obtained for the study
population.
RESULTS
Twelve patients underwent LITT at our institution for a total
of 13 procedures performed by two neurosurgeons (Table 1).
One patient underwent two LITT ablations on separate dates
approximately 7 months apart for anatomically distinct
lesions and locations. Of these 12 patients, 10 had brain
metastases from solid malignancies and 2 had glioblastoma
multiforme. Non-small cell lung cancer was the most com-
monly treated histology (6 patients, 50%). The median age of
patients on the day of the LITT procedure was 58.4 years,
and 66.7% of treated patients were female. All but one
patient received focal radiation prior to LITT, and the major-
ity of patients received multiple prior therapies. The most
common site of LITT ablation was in the frontal cortex (7 pro-
cedures, 53.8%), and both supratentorial and infratentorial
lesions were treated. Biopsy for intraoperative frozen sec-
tion, followed by formal pathology review, was obtained in
the majority of procedures (10 procedures, 76.9%) prior to
laser-induced tissue ablation. Pathology revealed treatment
effect in seven cases and viable tumor in three cases.
Three patients were on steroids prior to LITT for a
median duration of 70 days (range, 7–83). Of those, two
(66.7%) were able to taper off steroids during the initial
attempt. All nine additional patients were started on ste-
roids after LITT per standard protocol, and six were success-
fully weaned on initial steroid taper. The median duration
of post-LITT steroids was 32 days, with a range of 6–300.
One patient was lost to follow-up and not included in this
calculation. Reasons for failure of initial taper included sei-
zure (grade 3) and worsening weakness (grade 2).
Table 1. Clinical and demographic features of 12 patients


















Radiation alone 2 (15.4)
Chemoradiation 1 (7.7)
Resection + radiation 2 (15.4)























Pathology of brain lesion
obtained during LITT
Viable tumor 3 (23.1)
Necrosis/treatment effect 7 (53.8)
No biopsy 3 (23.1)



























Focal motor weakness 4 (30.8)
Infection 0 (0)
Hemorrhage 0 (0)
a13 lesions treated in 12 patients.
bMedian calculated for 12 procedures, as one patient was lost to
follow-up.
cTreatment given for subsequent progression of disease during the
course of follow-up for this study.
Abbreviations: CNS, central nervous system; GBM, glioblastoma
multiforme; LITT, laser interstitial thermal therapy; NSCLC, non-small
cell lung cancer.
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Focal motor weakness was the most common neurologic
impairment after LITT in four patients, for which three
patients required inpatient rehabilitation stays to regain
function prior to discharge home. One of these patients had
weakness prior to LITT and another had preceding ambula-
tory dysfunction. All four patients who developed weakness
had lesions that were either in, immediately adjacent, or
near the motor cortex or corticospinal motor tracts.
Of all patients who underwent LITT at our institution,
four have subsequently died (33.3%), including one from
unknown causes 8.1 months after LITT, one from pulmonary
hemorrhage 27.4 months after LITT, and two from progres-
sion of intracranial disease 9.9 months and 19.4 months,
respectively, after LITT (Table 2).
DISCUSSION
Our findings indicate that LITT is a well-tolerated procedure,
allowing some patients to discontinue steroids, that may be
effective for diagnosing and treating radiation necrosis and
tumor progression. In the setting of suspected radiation
necrosis, deciding between bevacizumab, LITT, or observa-
tion is complex. Patients selected for LITT were those for
whom there was (a) increasing size of contrast enhancement,
(b) diagnostic uncertainty between necrosis/treatment effects
and recurrent tumor, (c) an increasing concern of the possi-
bility of recurrence, and (d) progressive symptomatology.
Interpretation of post-LITT imaging remains an area of
active research. Contrast-enhancing volume increases after
LITT on the 3-month postoperative MRI and then gradually
starts to decrease over the 6-month and 1-year MRIs in
patients who are responsive to LITT. Similarly, diffusion
imaging shows initial increased diffusion restriction on dif-
fusion weighted imaging in the center of the lesion, likely
due to the central area of necrosis of the lesion, and then
diminishes over time.
The analysis is limited by sample size and its retrospec-
tive, single-institution design. Ultimately, well-designed ran-
domized trials comparing treatment modalities are needed
to further elucidate the efficacy and safety of this novel
therapy.
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